Turnstone Biologics (TSBX) Expected to Announce Earnings on Thursday

Turnstone Biologics (NASDAQ:TSBX) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Turnstone Biologics to post earnings of ($0.80) per share for the quarter.

Turnstone Biologics Trading Down 8.5 %

Shares of NASDAQ:TSBX opened at $0.35 on Thursday. Turnstone Biologics has a 12-month low of $0.34 and a 12-month high of $3.88. The business has a 50 day moving average of $0.43 and a two-hundred day moving average of $0.50. The company has a market capitalization of $8.19 million, a PE ratio of -0.11 and a beta of 2.04.

Analyst Ratings Changes

A number of research firms have weighed in on TSBX. Piper Sandler cut shares of Turnstone Biologics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $3.75 to $0.40 in a research report on Wednesday, February 5th. Bank of America cut Turnstone Biologics from a “neutral” rating to an “underperform” rating in a report on Friday, November 15th.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.